This review assessed cilostazol, beraprost sodium and prostaglandin E1 (PGE1) for treating intermittent claudication to improve walking distance. The authors concluded that cilostazol and PGE1 are effective, but further studies ofberaprost sodium are needed. A narrow literature search limits the reliability of these conclusions.
Data extraction
The authors did not state how the data were extracted for the review, or how many reviewers performed the data extraction. The mean value and standard deviation were extracted for MWD and PFWD at baseline, and for changes immediately following the treatment period, at 4 weeks after the commencement of treatment, and at the end of the maximum follow-up period after treatment. The number of participants experiencing adverse events was also extracted for each study and used to calculate the odds ratio (OR) with 95% confidence intervals (CIs).
Methods of synthesis
How were the studies combined? Studies rated as moderate or high quality were combined using meta-analysis, employing a fixed-effect model with studies weighted by sample size, to derive pooled effect sizes and 95% CIs for each drug and outcome. For MWD and PFWD, the weighted mean difference (WMD) was calculated using the general variance method; for adverse events, the pooled OR was estimated using the Mantel-Haenszel method. If statistical heterogeneity was detected, the pooled estimate was calculated using a random-effects model (DerSimonian and Laird) instead.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the Q statistic with a P-value of less than 0.05 judged to be statistically significant.
Results of the review
The review included 11 RCTs (n=2,131).
All 11 studies were rated as being of moderate quality, with scores ranging from 54 to 66. Cilostazol (6 RCTs, 1,352 participants).
Effectiveness: at the end of the treatment period (ranging from 12 to 24 weeks), cilostazol had a significantly greater effect than placebo on both the MWD (WMD +52.19 m, 95% CI: 32.08, 72.31; 5 RCTs) and PFWD (WMD +39.75 m, 95% CI: 23.39, 56.10; 3 RCTs). Similar smaller, but still statistically significant, effects were seen 4 weeks into treatment (3 RCTs). Only one RCT reported follow-up after the end of treatment. This trial found no significant effect of cilastazol over placebo 6 weeks after active treatment ceased.
Adverse events: the drop-out rate was significantly higher in the cilostazol group than in the placebo group (OR 1.98, 95% CI: 1.27, 3.07; 5 RCTs). The death rates were similar in the cilostazol and placebo groups (5 RCTs; 0.7% in each group), and there was no significant difference between the groups in the rate of serious adverse events (4 RCTs). Adverse effects that were more common in those taking cilostazol included headache, dizziness, palpitation, diarrhoea and abnormal stool.
Beraprost (2 RCTs, 505 participants).
Effectiveness: one RCT reported changes in MWD and PFWD after 12 weeks; these were not statistically significantly greater in the beraprost group than in the placebo group.
Adverse events: beraprost was associated with significantly more headaches (2 RCTs), flushes (1 RCT) and vasodilation (1 RCT).
PGE1 (3 RCTs, 274 participants).
Effectiveness: at the end of the treatment period (4 weeks in 2 RCTs, 8 weeks in the other), PGE1 had a significantly greater effect than placebo on both the MWD (WMD +100.27 m, 95% CI: 15.76, 184.78; 3 RCTs) and PFWD (WMD +55.73 m, 95% CI: 21.54, 89.92; 3 RCTs). The results were similar when the analysis was at 4 weeks. Two RCTs reported follow-up after the end of treatment (one after 12 weeks and the other after 8 weeks), but found no benefit of PGE1 over placebo for either MWD or PFWD.
